Somatostatin receptor (SSTR) imaging with 68Ga-DOTATATE PET/CT and its comparison with 18F-FDG PET/CT in patients with estrogen receptor positive (ER positive) metastatic breast cancer (mBC)

All India Institute of Medical Sciences, New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1. Biopsy proven estrogen receptor positive metastatic breast cancer
•2. Patients who have undergone 18F-FDG PET/CT for staging/re-staging within the last 3 weeks
•3. At least one site of known active disease on imaging within 3 months
•4. If a woman is of childbearing potential, a negative urine pregnancy test before administration of SSTR-targeted PET radiotracer would be mandatory.

•1. Pregnant and lactating females
•2. Patients who refuse to give written informed consent
•3. Unable to give informed consent or withdrawal of consent any point of time
•4. Recent anti-cancer chemotherapy/surgery in less than four weeks or radiotherapy in less than eight weeks
•5. Use of long-acting SSTR-targeting agents (example: lanreotide) within 28 days of SSTR-targeted imaging
•6. Use of short-acting SSTR-targeting agents (example: sandostatin) within 24 hours of SSTR-targeted imaging
•7. Concurrent primary malignancy other than known metastatic breast cancer, except adequately treated carcinoma in situ, non-melanoma carcinoma of the skin or any other curatively treated malignancy that has achieved complete response and is not expected to require treatment for recurrence during participation in the study
•8. Subjects with allergy/hypersensitivity to SSTR-targeted imaging agents
•9. Current use of high-dose glucocorticoids (>= 20 mg prednisone per day or equivalent)
•10. Active serious infection not controlled by antibiotics

发起方

All India Institute of Medical Sciences, New Delhi